Anna Piggin

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma

Anna Piggin, H. Miles Prince

INTRODUCTION: Despite therapeutic advances, myeloma remains an essentially incurable disease, with a median survival of approximately 8 - 10 years. Most patients will develop disease that is refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), and treatment regimens containing drugs with …

au (code pays fourni par la source)

A novel germline splice site DDX41 mutation causing MDS/AML.

Anna Piggin, Lucy C. Fox, Miles Prince

Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma

Emma Bayly, Vuong Nguyen, Adrian Binek, Anna Piggin et autres

Abstract Background Minimal residual disease (MRD) assessment of hematopoietic neoplasia below 10−4 requires more leukocytes than is usually attainable by post‐lysis preparation. However, not all laboratories are resourced for consensus Euroflow pre‐lysis methodology. Our study aim was to validate a modified pre‐lysis …

au (code pays fourni par la source)

Novel agents versus chemotherapy as frontline treatment of CLL

Anna Piggin, Emma Bayly, Constantine S. Tam

Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase …

au (code pays fourni par la source)

Outcomes of haematology/oncology patients admitted to intensive care unit at T he C anberra H ospital

Sagun Parakh, Anna Piggin, Teresa Neeman, Imogen Mitchell et autres

BACKGROUND: Outcomes for haematology/oncology patients have improved; however, determining their suitability for intensive care unit (ICU) admission remains challenging and controversial. AIM: Examine outcomes of patients admitted to an Australian tertiary hospital ICU and explore potential prognostic factors. METHODS: A retrospective review …

au (code pays fourni par la source)